As AI becomes embedded across pharmacovigilance, the skills required of safety scientists are rapidly evolving. This article examines the shifting balance between human expertise and AI-enabled tools, outlining the competencies, training pathways, and cultural changes needed to prepare tomorrow’s hybrid PV workforce.
HEOR is taking on a broader role within modern CROs. In this podcast conversation hosted by HealthEconomics.com, UBC's Aaron Berger and Dr. Mir Sohail Fazeli discuss how integrated evidence delivery, strong methodology, and real‑world context are shaping the next generation of evidence strategies.
The history of depression treatment reflects a centuries-old tension between mind and body—and how we conceptualize the condition has always shaped how we treat it. Today, with up to 30% of patients classified as treatment-resistant, psychedelic-assisted therapies are attracting serious scientific and regulatory attention. But emerging evidence suggests that the therapeutic context surrounding these treatments—relationships, setting, and social environment—may matter as much as the compounds themselves.
Linking longitudinal real-world data (RWD) to clinical study data offers deeper insights for drug developers. Contextualize study outcomes, extend data collection after the study ends, close the efficacy-effectiveness gap, and identify post-market patterns.
UBC Pharmacovigilance experts, Dobrochna Dolicka, Christopher Henry, Alix Garcia and Irene Navarro presented at DIA Europe 2025 on how AI can be used to streamline pharmacovigilance activities and how harmonization of guidelines can be enhanced in order to define a specific framework for gene therapy.
Psychedelic-assisted therapies are starting to emerge with potential as treatments for mental health conditions. Explore the evidence behind an increased interest in this use of substances such as psilocybin, MDMA, LSD, and DMT, and the future of research in this area.
Catherine Miller, MSN, CRNP, FNP-BC
Senior Project Manager, Safety, Epidemiology, Registries and Risk Management
Adherence is critical to ensuring patients receive full therapeutic benefit and effectively manage their disease, particularly for complex treatments such as injectables or infusions. Explore strategies to support patients and improve adherence in the blog.
Learn about the FDA's new guidance, the challenges of standardization, and how UBC is driving innovation in REMS implementation using modern APIs from UBC's VP of Data Intelligence and Program Analytics, Jim Shamp.
Discover UBC's insights from the Cell & Gene Meeting on the Mesa, the unique challenges patients face, and the importance of tailored support services to ensure successful treatment journeys
Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.
With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.